Investment
Features
FeesSafety
Academy
More
Pluang+

SailPoint Q2 revenue slightly misses estimates but shows strong ARR growth and EPS beat.

Company Fundamentals
09 Sep 2026
Tony Dante
View Source
Neutral
SailPoint Q2 revenue slightly misses estimates but shows strong ARR growth and EPS beat.

SailPoint reported Q2 2026 earnings with revenue of $308.81 million, slightly below estimates but up 17% year-over-year. Adjusted EPS of $0.09 beat analyst expectations by 12.5%, reflecting improved profitability. The company showed strong subscription growth, with total Annual Recurring Revenue (ARR) rising 25% to $1.231 billion and SaaS ARR up 36% to $847 million. Despite the revenue miss, SailPoint's solid ARR growth and low debt position highlight its strength in the cybersecurity market focused on identity security solutions.

More News

Korn Ferry beats Q1 earnings and revenue estimates but stock dips on cautious Q2 outlook

Korn Ferry beats Q1 earnings and revenue estimates but stock dips on cautious Q2 outlook

Korn Ferry reported strong Q1 results with earnings per share of $1.43 and revenue of $756.5 million, both exceeding analyst expectations and marking continued growth. Despite this, the stock fell due to conservative guidance for the next quarter, wh...

Company Fundamentals
Neutral
1 hour ago
The Cooper Companies forecast Q3 EPS of $1.12 and $1.10B revenue, with an analyst raising price target to $80.

The Cooper Companies forecast Q3 EPS of $1.12 and $1.10B revenue, with an analyst raising price target to $80.

The Cooper Companies is set to report its Q3 2026 earnings with analysts expecting earnings per share (EPS) of $1.12 and revenue of $1.10 billion, both showing growth from the previous year. Despite a recent 2.7% drop in stock price to $67.69, an ana...

Company Fundamentals
Bullish
2 hours ago
Intellia Therapeutics gains as FDA grants Priority Review for HAE treatment and analyst hikes price target.

Intellia Therapeutics gains as FDA grants Priority Review for HAE treatment and analyst hikes price target.

Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...

Analyst Insights
Bullish
3 hours ago
Signet Jewelers beats Q2 earnings estimates, raises full-year profit forecast, shares jump 14%.

Signet Jewelers beats Q2 earnings estimates, raises full-year profit forecast, shares jump 14%.

Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...

Company Fundamentals
Bullish
3 hours ago
UBS raises ABM Industries price target to $51.50 after strong earnings and revenue growth.

UBS raises ABM Industries price target to $51.50 after strong earnings and revenue growth.

UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App